PanCareSurPass Project HL7 FHIR Implementation Guide
0.1.0 - trial-use
150
PanCareSurPass Project HL7 FHIR Implementation Guide
0.1.0 - trial-use
150
This page is part of the PanCareSurPass Project HL7 FHIR Implementation Guide (v0.1.0: QA Preview) based on FHIR R4. This is the current published version. For a full list of available versions, see the Directory of published versions 
| Active as of 2023-01-26 |
@prefix fhir: <http://hl7.org/fhir/> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix rdfs: <http://www.w3.org/2000/01/rdf-schema#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .
# - resource -------------------------------------------------------------------
a fhir:CodeSystem;
fhir:nodeRole fhir:treeRoot;
fhir:Resource.id [ fhir:value "cs-riskfactor-eu-pcsp"]; #
fhir:DomainResource.text [
fhir:Narrative.status [ fhir:value "generated" ];
fhir:Narrative.div "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>This code system <code>http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp</code> defines the following codes:</p><table class=\"codes\"><tr><td style=\"white-space:nowrap\"><b>Code</b></td><td><b>Display</b></td><td><b>Definition</b></td></tr><tr><td style=\"white-space:nowrap\">1.1<a name=\"cs-riskfactor-eu-pcsp-1.461\"> </a></td><td>RT to a vol exposing the thyroid gland</td><td>RT to a vol exposing the thyroid gland</td></tr><tr><td style=\"white-space:nowrap\">1.2<a name=\"cs-riskfactor-eu-pcsp-1.462\"> </a></td><td>TBI</td><td>TBI</td></tr><tr><td style=\"white-space:nowrap\">1.3<a name=\"cs-riskfactor-eu-pcsp-1.463\"> </a></td><td>MIBG therapy (I-131 MIBG therapy)</td><td>MIBG therapy (I-131 MIBG therapy)</td></tr><tr><td style=\"white-space:nowrap\">2.1<a name=\"cs-riskfactor-eu-pcsp-2.461\"> </a></td><td>RT >= 10 Gy to a vol exposing the breasts</td><td>RT >= 10 Gy to a vol exposing the breasts</td></tr><tr><td style=\"white-space:nowrap\">2.2<a name=\"cs-riskfactor-eu-pcsp-2.462\"> </a></td><td>OR upper abdominal field radiation that can extend above the diaphragm likely exposing breast tissue at a young age</td><td>OR upper abdominal field radiation that can extend above the diaphragm likely exposing breast tissue at a young age</td></tr><tr><td style=\"white-space:nowrap\">3.1<a name=\"cs-riskfactor-eu-pcsp-3.461\"> </a></td><td>RT >= 35 Gy to a vol exposing the heart</td><td>RT >= 35 Gy to a vol exposing the heart</td></tr><tr><td style=\"white-space:nowrap\">3.2<a name=\"cs-riskfactor-eu-pcsp-3.462\"> </a></td><td>Anthracyclines (doxorubicin isotoxic equivalents)>= 250 mg/m2</td><td>Anthracyclines (doxorubicin isotoxic equivalents)>= 250 mg/m2</td></tr><tr><td style=\"white-space:nowrap\">3.3<a name=\"cs-riskfactor-eu-pcsp-3.463\"> </a></td><td>RT >= 15 Gy to a vol exposing the heart AND Anthracyclines (doxorubicin isotoxic equivalents)>= 100 mg/m2</td><td>RT >= 15 Gy to a vol exposing the heart AND Anthracyclines (doxorubicin isotoxic equivalents)>= 100 mg/m2</td></tr><tr><td style=\"white-space:nowrap\">4.1<a name=\"cs-riskfactor-eu-pcsp-4.461\"> </a></td><td>Alkylating agents</td><td>Alkylating agents</td></tr><tr><td style=\"white-space:nowrap\">4.2<a name=\"cs-riskfactor-eu-pcsp-4.462\"> </a></td><td>RT to a vol exposing the testes</td><td>RT to a vol exposing the testes</td></tr><tr><td style=\"white-space:nowrap\">5.1<a name=\"cs-riskfactor-eu-pcsp-5.461\"> </a></td><td>RT between 15 and 35 Gy to a vol exposing the heart</td><td>RT between 15 and 35 Gy to a vol exposing the heart</td></tr><tr><td style=\"white-space:nowrap\">6.1<a name=\"cs-riskfactor-eu-pcsp-6.461\"> </a></td><td>RT to a vol exposing the testes or pelvis</td><td>RT to a vol exposing the testes or pelvis</td></tr><tr><td style=\"white-space:nowrap\">6.3<a name=\"cs-riskfactor-eu-pcsp-6.463\"> </a></td><td>Surgery to the spinal cord, sympathetic nerves or pelvis</td><td>Surgery to the spinal cord, sympathetic nerves or pelvis</td></tr><tr><td style=\"white-space:nowrap\">6.4<a name=\"cs-riskfactor-eu-pcsp-6.464\"> </a></td><td>Hypogonadal</td><td>Hypogonadal</td></tr><tr><td style=\"white-space:nowrap\">7.2<a name=\"cs-riskfactor-eu-pcsp-7.462\"> </a></td><td>RT to a vol exposing the ovaries</td><td>RT to a vol exposing the ovaries</td></tr><tr><td style=\"white-space:nowrap\">8.1<a name=\"cs-riskfactor-eu-pcsp-8.461\"> </a></td><td>RT >= 30 Gy to a vol exposing the head or the brain</td><td>RT >= 30 Gy to a vol exposing the head or the brain</td></tr><tr><td style=\"white-space:nowrap\">8.2<a name=\"cs-riskfactor-eu-pcsp-8.462\"> </a></td><td>Cisplatin (with or without carboplatin > 1500 mg/m2)</td><td>Cisplatin (with or without carboplatin > 1500 mg/m2)</td></tr><tr><td style=\"white-space:nowrap\">9.1<a name=\"cs-riskfactor-eu-pcsp-9.461\"> </a></td><td>RT to a vol exposing the pancreas</td><td>RT to a vol exposing the pancreas</td></tr><tr><td style=\"white-space:nowrap\">10.2<a name=\"cs-riskfactor-eu-pcsp-10.462\"> </a></td><td>HSCT</td><td>HSCT</td></tr><tr><td style=\"white-space:nowrap\">11.1<a name=\"cs-riskfactor-eu-pcsp-11.461\"> </a></td><td>RT to a volume exposing the hypothalamus or pituatary gland</td><td>RT to a volume exposing the hypothalamus or pituatary gland</td></tr><tr><td style=\"white-space:nowrap\">11.3<a name=\"cs-riskfactor-eu-pcsp-11.463\"> </a></td><td>Hypothalamic or pituitary tumour</td><td>Hypothalamic or pituitary tumour</td></tr><tr><td style=\"white-space:nowrap\">11.4<a name=\"cs-riskfactor-eu-pcsp-11.464\"> </a></td><td>Neurosurgery of the hypothalamus or pituitary gland</td><td>Neurosurgery of the hypothalamus or pituitary gland</td></tr><tr><td style=\"white-space:nowrap\">12.1<a name=\"cs-riskfactor-eu-pcsp-12.461\"> </a></td><td>RT to a vol exposing the kidneys, heart and associated large vessels</td><td>RT to a vol exposing the kidneys, heart and associated large vessels</td></tr><tr><td style=\"white-space:nowrap\">12.3<a name=\"cs-riskfactor-eu-pcsp-12.463\"> </a></td><td>Nephrectomy</td><td>Nephrectomy</td></tr><tr><td style=\"white-space:nowrap\">12.4<a name=\"cs-riskfactor-eu-pcsp-12.464\"> </a></td><td>Ifosfamide</td><td>Ifosfamide</td></tr><tr><td style=\"white-space:nowrap\">12.5<a name=\"cs-riskfactor-eu-pcsp-12.465\"> </a></td><td>Platinium based chemotherapy</td><td>Platinium based chemotherapy</td></tr><tr><td style=\"white-space:nowrap\">12.6<a name=\"cs-riskfactor-eu-pcsp-12.466\"> </a></td><td>Nitrosureas</td><td>Nitrosureas</td></tr><tr><td style=\"white-space:nowrap\">12.7<a name=\"cs-riskfactor-eu-pcsp-12.467\"> </a></td><td>Immunosuppressives treatment and prolonged steroids as anticancer treatment (at least 4 weeks, continuously)</td><td>Immunosuppressives treatment and prolonged steroids as anticancer treatment (at least 4 weeks, continuously)</td></tr><tr><td style=\"white-space:nowrap\">13.1<a name=\"cs-riskfactor-eu-pcsp-13.461\"> </a></td><td>Cranial and/or spinal RT</td><td>Cranial and/or spinal RT</td></tr><tr><td style=\"white-space:nowrap\">13.3<a name=\"cs-riskfactor-eu-pcsp-13.463\"> </a></td><td>Methotrexate</td><td>Methotrexate</td></tr><tr><td style=\"white-space:nowrap\">13.4<a name=\"cs-riskfactor-eu-pcsp-13.464\"> </a></td><td>Gonadal failure</td><td>Gonadal failure</td></tr><tr><td style=\"white-space:nowrap\">13.5<a name=\"cs-riskfactor-eu-pcsp-13.465\"> </a></td><td>Growth hormone deficiency</td><td>Growth hormone deficiency</td></tr><tr><td style=\"white-space:nowrap\">13.6<a name=\"cs-riskfactor-eu-pcsp-13.466\"> </a></td><td>Prolonged (at least 4 weeks, continuously) corticosteroids as anti-cancer treatment</td><td>Prolonged (at least 4 weeks, continuously) corticosteroids as anti-cancer treatment</td></tr><tr><td style=\"white-space:nowrap\">14.3<a name=\"cs-riskfactor-eu-pcsp-14.463\"> </a></td><td>High dose RT</td><td>High dose RT</td></tr><tr><td style=\"white-space:nowrap\">15.1<a name=\"cs-riskfactor-eu-pcsp-15.461\"> </a></td><td>Radiotherapy to a vol exposing the HP region >= 30 Gy</td><td>Radiotherapy to a vol exposing the HP region >= 30 Gy</td></tr><tr><td style=\"white-space:nowrap\">15.2<a name=\"cs-riskfactor-eu-pcsp-15.462\"> </a></td><td>Surgery near or within the HP region</td><td>Surgery near or within the HP region</td></tr><tr><td style=\"white-space:nowrap\">15.3<a name=\"cs-riskfactor-eu-pcsp-15.463\"> </a></td><td>CNS tumours near or within the HP region</td><td>CNS tumours near or within the HP region</td></tr><tr><td style=\"white-space:nowrap\">16.1<a name=\"cs-riskfactor-eu-pcsp-16.461\"> </a></td><td>Radiotherapy to a vol exposing the HP region< 30 Gy</td><td>Radiotherapy to a vol exposing the HP region< 30 Gy</td></tr><tr><td style=\"white-space:nowrap\">16.2<a name=\"cs-riskfactor-eu-pcsp-16.462\"> </a></td><td>Hydrocephalus or cerebrospinal fluid shunt (Risk factor for GHD)</td><td>Hydrocephalus or cerebrospinal fluid shunt (Risk factor for GHD)</td></tr><tr><td style=\"white-space:nowrap\">17.1<a name=\"cs-riskfactor-eu-pcsp-17.461\"> </a></td><td>Radiotherapy to a vol exposing the HP region</td><td>Radiotherapy to a vol exposing the HP region</td></tr><tr><td style=\"white-space:nowrap\">17.3<a name=\"cs-riskfactor-eu-pcsp-17.463\"> </a></td><td>Surgery near or within the HP region</td><td>Surgery near or within the HP region</td></tr><tr><td style=\"white-space:nowrap\">18.1<a name=\"cs-riskfactor-eu-pcsp-18.461\"> </a></td><td>Radiotherapy to a vol exposing the HP region</td><td>Radiotherapy to a vol exposing the HP region</td></tr><tr><td style=\"white-space:nowrap\">18.3<a name=\"cs-riskfactor-eu-pcsp-18.463\"> </a></td><td>Surgery near or within the HP region</td><td>Surgery near or within the HP region</td></tr><tr><td style=\"white-space:nowrap\">19.1<a name=\"cs-riskfactor-eu-pcsp-19.461\"> </a></td><td>RT to a vol exposing the thyroid gland</td><td>RT to a vol exposing the thyroid gland</td></tr><tr><td style=\"white-space:nowrap\">19.3<a name=\"cs-riskfactor-eu-pcsp-19.463\"> </a></td><td>Radioiodine therapy (I-131 ablation therapy)</td><td>Radioiodine therapy (I-131 ablation therapy)</td></tr><tr><td style=\"white-space:nowrap\">19.5<a name=\"cs-riskfactor-eu-pcsp-19.465\"> </a></td><td>Allogenic HSCT</td><td>Allogenic HSCT</td></tr><tr><td style=\"white-space:nowrap\">19.6<a name=\"cs-riskfactor-eu-pcsp-19.466\"> </a></td><td>Total thyroidectomy</td><td>Total thyroidectomy</td></tr><tr><td style=\"white-space:nowrap\">20.1<a name=\"cs-riskfactor-eu-pcsp-20.461\"> </a></td><td>RT to a vol exposing the head, brain or neck</td><td>RT to a vol exposing the head, brain or neck</td></tr><tr><td style=\"white-space:nowrap\">21.1<a name=\"cs-riskfactor-eu-pcsp-21.461\"> </a></td><td>History of a central nervous system tumor</td><td>History of a central nervous system tumor</td></tr><tr><td style=\"white-space:nowrap\">21.2<a name=\"cs-riskfactor-eu-pcsp-21.462\"> </a></td><td>RT to a vol exposing the brain ANY DOSE</td><td>RT to a vol exposing the brain ANY DOSE</td></tr><tr><td style=\"white-space:nowrap\">21.4<a name=\"cs-riskfactor-eu-pcsp-21.464\"> </a></td><td>Brain surgery</td><td>Brain surgery</td></tr><tr><td style=\"white-space:nowrap\">21.5<a name=\"cs-riskfactor-eu-pcsp-21.465\"> </a></td><td>High dose cytarabine IV (intravenous)</td><td>High dose cytarabine IV (intravenous)</td></tr><tr><td style=\"white-space:nowrap\">21.6<a name=\"cs-riskfactor-eu-pcsp-21.466\"> </a></td><td>High dose MTX IV</td><td>High dose MTX IV</td></tr><tr><td style=\"white-space:nowrap\">21.7<a name=\"cs-riskfactor-eu-pcsp-21.467\"> </a></td><td>Any Chemotherapy IT (intrathecal)</td><td>Any Chemotherapy IT (intrathecal)</td></tr><tr><td style=\"white-space:nowrap\">22.1<a name=\"cs-riskfactor-eu-pcsp-22.461\"> </a></td><td>Vinca-Alkaloids</td><td>Vinca-Alkaloids</td></tr><tr><td style=\"white-space:nowrap\">22.2<a name=\"cs-riskfactor-eu-pcsp-22.462\"> </a></td><td>Cisplatin or carboplatin</td><td>Cisplatin or carboplatin</td></tr><tr><td style=\"white-space:nowrap\">23.1<a name=\"cs-riskfactor-eu-pcsp-23.461\"> </a></td><td>RT to a vol exposing the lens</td><td>RT to a vol exposing the lens</td></tr><tr><td style=\"white-space:nowrap\">24.1<a name=\"cs-riskfactor-eu-pcsp-24.461\"> </a></td><td>RT to a vol exposing the eye and orbit</td><td>RT to a vol exposing the eye and orbit</td></tr><tr><td style=\"white-space:nowrap\">24.3<a name=\"cs-riskfactor-eu-pcsp-24.463\"> </a></td><td>Radioiodine therapy (I-131 ablation therapy)</td><td>Radioiodine therapy (I-131 ablation therapy)</td></tr><tr><td style=\"white-space:nowrap\">25.1<a name=\"cs-riskfactor-eu-pcsp-25.461\"> </a></td><td>RT to a vol exposing the craniofacial area, especially after high doses and at a young age</td><td>RT to a vol exposing the craniofacial area, especially after high doses and at a young age</td></tr><tr><td style=\"white-space:nowrap\">25.3<a name=\"cs-riskfactor-eu-pcsp-25.463\"> </a></td><td>Surgery to the face, especially at a young age</td><td>Surgery to the face, especially at a young age</td></tr><tr><td style=\"white-space:nowrap\">26.1<a name=\"cs-riskfactor-eu-pcsp-26.461\"> </a></td><td>Surgery of the spine</td><td>Surgery of the spine</td></tr><tr><td style=\"white-space:nowrap\">26.2<a name=\"cs-riskfactor-eu-pcsp-26.462\"> </a></td><td>Surgery of the chest (Does not include CVC pose)</td><td>Surgery of the chest (Does not include CVC pose)</td></tr><tr><td style=\"white-space:nowrap\">26.3<a name=\"cs-riskfactor-eu-pcsp-26.463\"> </a></td><td>RT to a vol exposing the spine</td><td>RT to a vol exposing the spine</td></tr><tr><td style=\"white-space:nowrap\">26.4<a name=\"cs-riskfactor-eu-pcsp-26.464\"> </a></td><td>Spinal or paraspinal malignancies</td><td>Spinal or paraspinal malignancies</td></tr><tr><td style=\"white-space:nowrap\">27.1<a name=\"cs-riskfactor-eu-pcsp-27.461\"> </a></td><td>Cyclophosphamide</td><td>Cyclophosphamide</td></tr><tr><td style=\"white-space:nowrap\">27.3<a name=\"cs-riskfactor-eu-pcsp-27.463\"> </a></td><td>RT to a vol exposing the bladder</td><td>RT to a vol exposing the bladder</td></tr><tr><td style=\"white-space:nowrap\">27.5<a name=\"cs-riskfactor-eu-pcsp-27.465\"> </a></td><td>Cystectomy</td><td>Cystectomy</td></tr><tr><td style=\"white-space:nowrap\">27.6<a name=\"cs-riskfactor-eu-pcsp-27.466\"> </a></td><td>Hysterectomy</td><td>Hysterectomy</td></tr><tr><td style=\"white-space:nowrap\">27.7<a name=\"cs-riskfactor-eu-pcsp-27.467\"> </a></td><td>Pelvic surgery</td><td>Pelvic surgery</td></tr><tr><td style=\"white-space:nowrap\">27.8<a name=\"cs-riskfactor-eu-pcsp-27.468\"> </a></td><td>Spinal cord surgery</td><td>Spinal cord surgery</td></tr><tr><td style=\"white-space:nowrap\">28.1<a name=\"cs-riskfactor-eu-pcsp-28.461\"> </a></td><td>RT to a vol exposing the uterus only female</td><td>RT to a vol exposing the uterus only female</td></tr><tr><td style=\"white-space:nowrap\">29.1<a name=\"cs-riskfactor-eu-pcsp-29.461\"> </a></td><td>RT to a vol exposing the oral cavity or salivary glands</td><td>RT to a vol exposing the oral cavity or salivary glands</td></tr><tr><td style=\"white-space:nowrap\">29.4<a name=\"cs-riskfactor-eu-pcsp-29.464\"> </a></td><td>Chemotherapy</td><td>Chemotherapy</td></tr><tr><td style=\"white-space:nowrap\">30.1<a name=\"cs-riskfactor-eu-pcsp-30.461\"> </a></td><td>RT to a vol exposing the gastro-intestinal tract</td><td>RT to a vol exposing the gastro-intestinal tract</td></tr><tr><td style=\"white-space:nowrap\">30.3<a name=\"cs-riskfactor-eu-pcsp-30.463\"> </a></td><td>Oesophageal surgery</td><td>Oesophageal surgery</td></tr><tr><td style=\"white-space:nowrap\">30.4<a name=\"cs-riskfactor-eu-pcsp-30.464\"> </a></td><td>Abdominal surgery</td><td>Abdominal surgery</td></tr><tr><td style=\"white-space:nowrap\">30.5<a name=\"cs-riskfactor-eu-pcsp-30.465\"> </a></td><td>With a history of chronic GVHD</td><td>With a history of chronic GVHD</td></tr><tr><td style=\"white-space:nowrap\">31.1<a name=\"cs-riskfactor-eu-pcsp-31.461\"> </a></td><td>Anthracyclines (doxorubicin isotoxic equivalents) <100 mg/m2</td><td>Anthracyclines (doxorubicin isotoxic equivalents) <100 mg/m2</td></tr><tr><td style=\"white-space:nowrap\">32.1<a name=\"cs-riskfactor-eu-pcsp-32.461\"> </a></td><td>RT to a vol exposing the lungs</td><td>RT to a vol exposing the lungs</td></tr><tr><td style=\"white-space:nowrap\">32.3<a name=\"cs-riskfactor-eu-pcsp-32.463\"> </a></td><td>Bleomycin</td><td>Bleomycin</td></tr><tr><td style=\"white-space:nowrap\">32.4<a name=\"cs-riskfactor-eu-pcsp-32.464\"> </a></td><td>Busulfan</td><td>Busulfan</td></tr><tr><td style=\"white-space:nowrap\">32.5<a name=\"cs-riskfactor-eu-pcsp-32.465\"> </a></td><td>BCNU Carmustine</td><td>BCNU Carmustine</td></tr><tr><td style=\"white-space:nowrap\">32.6<a name=\"cs-riskfactor-eu-pcsp-32.466\"> </a></td><td>CCNU Lomustine</td><td>CCNU Lomustine</td></tr><tr><td style=\"white-space:nowrap\">32.7<a name=\"cs-riskfactor-eu-pcsp-32.467\"> </a></td><td>Thoracic surgery</td><td>Thoracic surgery</td></tr><tr><td style=\"white-space:nowrap\">33.1<a name=\"cs-riskfactor-eu-pcsp-33.461\"> </a></td><td>Cisplatin Any dose</td><td>Cisplatin Any dose</td></tr><tr><td style=\"white-space:nowrap\">33.3<a name=\"cs-riskfactor-eu-pcsp-33.463\"> </a></td><td>Carboplatin Any dose</td><td>Carboplatin Any dose</td></tr><tr><td style=\"white-space:nowrap\">34.1<a name=\"cs-riskfactor-eu-pcsp-34.461\"> </a></td><td>RT to a volume exposing the liver</td><td>RT to a volume exposing the liver</td></tr><tr><td style=\"white-space:nowrap\">34.3<a name=\"cs-riskfactor-eu-pcsp-34.463\"> </a></td><td>HSCT (irrespective of GVHD)</td><td>HSCT (irrespective of GVHD)</td></tr><tr><td style=\"white-space:nowrap\">34.5<a name=\"cs-riskfactor-eu-pcsp-34.465\"> </a></td><td>Mercaptopurine Thioguanine</td><td>Mercaptopurine Thioguanine</td></tr><tr><td style=\"white-space:nowrap\">34.6<a name=\"cs-riskfactor-eu-pcsp-34.466\"> </a></td><td>Dactinomycin</td><td>Dactinomycin</td></tr><tr><td style=\"white-space:nowrap\">34.8<a name=\"cs-riskfactor-eu-pcsp-34.468\"> </a></td><td>Chronic viral hepatitis</td><td>Chronic viral hepatitis</td></tr><tr><td style=\"white-space:nowrap\">34.9<a name=\"cs-riskfactor-eu-pcsp-34.469\"> </a></td><td>Sinusoidal obstruction syndrome</td><td>Sinusoidal obstruction syndrome</td></tr><tr><td style=\"white-space:nowrap\">34.10<a name=\"cs-riskfactor-eu-pcsp-34.4610\"> </a></td><td>Chronic GVHD</td><td>Chronic GVHD</td></tr><tr><td style=\"white-space:nowrap\">34.11<a name=\"cs-riskfactor-eu-pcsp-34.4611\"> </a></td><td>Liver surgery</td><td>Liver surgery</td></tr><tr><td style=\"white-space:nowrap\">35.2<a name=\"cs-riskfactor-eu-pcsp-35.462\"> </a></td><td>Multiple red blood cell transfusions</td><td>Multiple red blood cell transfusions</td></tr><tr><td style=\"white-space:nowrap\">36.1<a name=\"cs-riskfactor-eu-pcsp-36.461\"> </a></td><td>Splenectomy</td><td>Splenectomy</td></tr><tr><td style=\"white-space:nowrap\">36.2<a name=\"cs-riskfactor-eu-pcsp-36.462\"> </a></td><td>RT >= 10 Gy to a vol exposing the spleen</td><td>RT >= 10 Gy to a vol exposing the spleen</td></tr><tr><td style=\"white-space:nowrap\">36.4<a name=\"cs-riskfactor-eu-pcsp-36.464\"> </a></td><td>Autologus HSCT conditioned with TBI</td><td>Autologus HSCT conditioned with TBI</td></tr><tr><td style=\"white-space:nowrap\">37.1<a name=\"cs-riskfactor-eu-pcsp-37.461\"> </a></td><td>Hereditary cancer sd</td><td>Hereditary cancer sd</td></tr><tr><td style=\"white-space:nowrap\">38.1<a name=\"cs-riskfactor-eu-pcsp-38.461\"> </a></td><td>Any RT including TBI</td><td>Any RT including TBI</td></tr><tr><td style=\"white-space:nowrap\">39.1<a name=\"cs-riskfactor-eu-pcsp-39.461\"> </a></td><td>RT to a vol exposing the colon and rectum</td><td>RT to a vol exposing the colon and rectum</td></tr><tr><td style=\"white-space:nowrap\">40.1<a name=\"cs-riskfactor-eu-pcsp-40.461\"> </a></td><td>RT to a vol exposing the oral cavity</td><td>RT to a vol exposing the oral cavity</td></tr><tr><td style=\"white-space:nowrap\">41.2<a name=\"cs-riskfactor-eu-pcsp-41.462\"> </a></td><td>Anthracyclines and/or Mitoxantrone</td><td>Anthracyclines and/or Mitoxantrone</td></tr><tr><td style=\"white-space:nowrap\">41.3<a name=\"cs-riskfactor-eu-pcsp-41.463\"> </a></td><td>Epipodophyllotoxins or autologous</td><td>Epipodophyllotoxins or autologous</td></tr><tr><td style=\"white-space:nowrap\">41.4<a name=\"cs-riskfactor-eu-pcsp-41.464\"> </a></td><td>Autologous haematopoietic stem cell transplant</td><td>Autologous haematopoietic stem cell transplant</td></tr><tr><td style=\"white-space:nowrap\">42.1<a name=\"cs-riskfactor-eu-pcsp-42.461\"> </a></td><td>Ciclofosfamide, Ifosfamide (particularly if they have a history of severe hemorrhagic cystitis)</td><td>Ciclofosfamide, Ifosfamide (particularly if they have a history of severe hemorrhagic cystitis)</td></tr><tr><td style=\"white-space:nowrap\">42.2<a name=\"cs-riskfactor-eu-pcsp-42.462\"> </a></td><td>RT to a vol exposing the bladder</td><td>RT to a vol exposing the bladder</td></tr><tr><td style=\"white-space:nowrap\">44.1<a name=\"cs-riskfactor-eu-pcsp-44.461\"> </a></td><td>RT to a vol exposing the lungs</td><td>RT to a vol exposing the lungs</td></tr><tr><td style=\"white-space:nowrap\">45.1<a name=\"cs-riskfactor-eu-pcsp-45.461\"> </a></td><td>RT to a vol exposing the head or brain</td><td>RT to a vol exposing the head or brain</td></tr><tr><td style=\"white-space:nowrap\">46.2<a name=\"cs-riskfactor-eu-pcsp-46.462\"> </a></td><td>Anthracyclines (doxorubicin isotoxic equivalents) between 100 and 250 mg/m2</td><td>Anthracyclines (doxorubicin isotoxic equivalents) between 100 and 250 mg/m2</td></tr><tr><td style=\"white-space:nowrap\">47.1<a name=\"cs-riskfactor-eu-pcsp-47.461\"> </a></td><td>RT to a vol exposing the kidney or urinary tract</td><td>RT to a vol exposing the kidney or urinary tract</td></tr></table></div>"
]; #
fhir:CodeSystem.url [ fhir:value "http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp"]; #
fhir:CodeSystem.version [ fhir:value "0.1.0"]; #
fhir:CodeSystem.name [ fhir:value "CsRiskFactorPcsp"]; #
fhir:CodeSystem.title [ fhir:value "Risk Factors"]; #
fhir:CodeSystem.status [ fhir:value "active"]; #
fhir:CodeSystem.experimental [ fhir:value "false"^^xsd:boolean]; #
fhir:CodeSystem.date [ fhir:value "2023-01-26T10:15:52+01:00"^^xsd:dateTime]; #
fhir:CodeSystem.publisher [ fhir:value "PanCareSurPass Project"]; #
fhir:CodeSystem.contact [
fhir:index 0;
fhir:ContactDetail.name [ fhir:value "PanCareSurPass Project" ];
fhir:ContactDetail.telecom [
fhir:index 0;
fhir:ContactPoint.system [ fhir:value "url" ];
fhir:ContactPoint.value [ fhir:value "https://www.pancaresurpass.eu/" ] ]
], [
fhir:index 1;
fhir:ContactDetail.name [ fhir:value "PanCareSurPass Project" ];
fhir:ContactDetail.telecom [
fhir:index 0;
fhir:ContactPoint.system [ fhir:value "url" ];
fhir:ContactPoint.value [ fhir:value "https://www.pancaresurpass.eu/" ] ]
]; #
fhir:CodeSystem.description [ fhir:value "Risk Factors used by the PCSP algorithm"]; #
fhir:CodeSystem.jurisdiction [
fhir:index 0;
fhir:CodeableConcept.coding [
fhir:index 0;
fhir:Coding.system [ fhir:value "http://unstats.un.org/unsd/methods/m49/m49.htm" ];
fhir:Coding.code [ fhir:value "150" ];
fhir:Coding.display [ fhir:value "Europe" ] ]
]; #
fhir:CodeSystem.caseSensitive [ fhir:value "true"^^xsd:boolean]; #
fhir:CodeSystem.content [ fhir:value "complete"]; #
fhir:CodeSystem.count [ fhir:value "112"^^xsd:nonNegativeInteger]; #
fhir:CodeSystem.concept [
fhir:index 0;
fhir:CodeSystem.concept.code [ fhir:value "1.1" ];
fhir:CodeSystem.concept.display [ fhir:value "RT to a vol exposing the thyroid gland" ];
fhir:CodeSystem.concept.definition [ fhir:value "RT to a vol exposing the thyroid gland" ]
], [
fhir:index 1;
fhir:CodeSystem.concept.code [ fhir:value "1.2" ];
fhir:CodeSystem.concept.display [ fhir:value "TBI" ];
fhir:CodeSystem.concept.definition [ fhir:value "TBI" ]
], [
fhir:index 2;
fhir:CodeSystem.concept.code [ fhir:value "1.3" ];
fhir:CodeSystem.concept.display [ fhir:value "MIBG therapy (I-131 MIBG therapy)" ];
fhir:CodeSystem.concept.definition [ fhir:value "MIBG therapy (I-131 MIBG therapy)" ]
], [
fhir:index 3;
fhir:CodeSystem.concept.code [ fhir:value "2.1" ];
fhir:CodeSystem.concept.display [ fhir:value "RT >= 10 Gy to a vol exposing the breasts" ];
fhir:CodeSystem.concept.definition [ fhir:value "RT >= 10 Gy to a vol exposing the breasts" ]
], [
fhir:index 4;
fhir:CodeSystem.concept.code [ fhir:value "2.2" ];
fhir:CodeSystem.concept.display [ fhir:value "OR upper abdominal field radiation that can extend above the diaphragm likely exposing breast tissue at a young age" ];
fhir:CodeSystem.concept.definition [ fhir:value "OR upper abdominal field radiation that can extend above the diaphragm likely exposing breast tissue at a young age" ]
], [
fhir:index 5;
fhir:CodeSystem.concept.code [ fhir:value "3.1" ];
fhir:CodeSystem.concept.display [ fhir:value "RT >= 35 Gy to a vol exposing the heart" ];
fhir:CodeSystem.concept.definition [ fhir:value "RT >= 35 Gy to a vol exposing the heart" ]
], [
fhir:index 6;
fhir:CodeSystem.concept.code [ fhir:value "3.2" ];
fhir:CodeSystem.concept.display [ fhir:value "Anthracyclines (doxorubicin isotoxic equivalents)>= 250 mg/m2" ];
fhir:CodeSystem.concept.definition [ fhir:value "Anthracyclines (doxorubicin isotoxic equivalents)>= 250 mg/m2" ]
], [
fhir:index 7;
fhir:CodeSystem.concept.code [ fhir:value "3.3" ];
fhir:CodeSystem.concept.display [ fhir:value "RT >= 15 Gy to a vol exposing the heart AND Anthracyclines (doxorubicin isotoxic equivalents)>= 100 mg/m2" ];
fhir:CodeSystem.concept.definition [ fhir:value "RT >= 15 Gy to a vol exposing the heart AND Anthracyclines (doxorubicin isotoxic equivalents)>= 100 mg/m2" ]
], [
fhir:index 8;
fhir:CodeSystem.concept.code [ fhir:value "4.1" ];
fhir:CodeSystem.concept.display [ fhir:value "Alkylating agents" ];
fhir:CodeSystem.concept.definition [ fhir:value "Alkylating agents" ]
], [
fhir:index 9;
fhir:CodeSystem.concept.code [ fhir:value "4.2" ];
fhir:CodeSystem.concept.display [ fhir:value "RT to a vol exposing the testes" ];
fhir:CodeSystem.concept.definition [ fhir:value "RT to a vol exposing the testes" ]
], [
fhir:index 10;
fhir:CodeSystem.concept.code [ fhir:value "5.1" ];
fhir:CodeSystem.concept.display [ fhir:value "RT between 15 and 35 Gy to a vol exposing the heart" ];
fhir:CodeSystem.concept.definition [ fhir:value "RT between 15 and 35 Gy to a vol exposing the heart" ]
], [
fhir:index 11;
fhir:CodeSystem.concept.code [ fhir:value "6.1" ];
fhir:CodeSystem.concept.display [ fhir:value "RT to a vol exposing the testes or pelvis" ];
fhir:CodeSystem.concept.definition [ fhir:value "RT to a vol exposing the testes or pelvis" ]
], [
fhir:index 12;
fhir:CodeSystem.concept.code [ fhir:value "6.3" ];
fhir:CodeSystem.concept.display [ fhir:value "Surgery to the spinal cord, sympathetic nerves or pelvis" ];
fhir:CodeSystem.concept.definition [ fhir:value "Surgery to the spinal cord, sympathetic nerves or pelvis" ]
], [
fhir:index 13;
fhir:CodeSystem.concept.code [ fhir:value "6.4" ];
fhir:CodeSystem.concept.display [ fhir:value "Hypogonadal" ];
fhir:CodeSystem.concept.definition [ fhir:value "Hypogonadal" ]
], [
fhir:index 14;
fhir:CodeSystem.concept.code [ fhir:value "7.2" ];
fhir:CodeSystem.concept.display [ fhir:value "RT to a vol exposing the ovaries" ];
fhir:CodeSystem.concept.definition [ fhir:value "RT to a vol exposing the ovaries" ]
], [
fhir:index 15;
fhir:CodeSystem.concept.code [ fhir:value "8.1" ];
fhir:CodeSystem.concept.display [ fhir:value "RT >= 30 Gy to a vol exposing the head or the brain" ];
fhir:CodeSystem.concept.definition [ fhir:value "RT >= 30 Gy to a vol exposing the head or the brain" ]
], [
fhir:index 16;
fhir:CodeSystem.concept.code [ fhir:value "8.2" ];
fhir:CodeSystem.concept.display [ fhir:value "Cisplatin (with or without carboplatin > 1500 mg/m2)" ];
fhir:CodeSystem.concept.definition [ fhir:value "Cisplatin (with or without carboplatin > 1500 mg/m2)" ]
], [
fhir:index 17;
fhir:CodeSystem.concept.code [ fhir:value "9.1" ];
fhir:CodeSystem.concept.display [ fhir:value "RT to a vol exposing the pancreas" ];
fhir:CodeSystem.concept.definition [ fhir:value "RT to a vol exposing the pancreas" ]
], [
fhir:index 18;
fhir:CodeSystem.concept.code [ fhir:value "10.2" ];
fhir:CodeSystem.concept.display [ fhir:value "HSCT" ];
fhir:CodeSystem.concept.definition [ fhir:value "HSCT" ]
], [
fhir:index 19;
fhir:CodeSystem.concept.code [ fhir:value "11.1" ];
fhir:CodeSystem.concept.display [ fhir:value "RT to a volume exposing the hypothalamus or pituatary gland" ];
fhir:CodeSystem.concept.definition [ fhir:value "RT to a volume exposing the hypothalamus or pituatary gland" ]
], [
fhir:index 20;
fhir:CodeSystem.concept.code [ fhir:value "11.3" ];
fhir:CodeSystem.concept.display [ fhir:value "Hypothalamic or pituitary tumour" ];
fhir:CodeSystem.concept.definition [ fhir:value "Hypothalamic or pituitary tumour" ]
], [
fhir:index 21;
fhir:CodeSystem.concept.code [ fhir:value "11.4" ];
fhir:CodeSystem.concept.display [ fhir:value "Neurosurgery of the hypothalamus or pituitary gland" ];
fhir:CodeSystem.concept.definition [ fhir:value "Neurosurgery of the hypothalamus or pituitary gland" ]
], [
fhir:index 22;
fhir:CodeSystem.concept.code [ fhir:value "12.1" ];
fhir:CodeSystem.concept.display [ fhir:value "RT to a vol exposing the kidneys, heart and associated large vessels" ];
fhir:CodeSystem.concept.definition [ fhir:value "RT to a vol exposing the kidneys, heart and associated large vessels" ]
], [
fhir:index 23;
fhir:CodeSystem.concept.code [ fhir:value "12.3" ];
fhir:CodeSystem.concept.display [ fhir:value "Nephrectomy" ];
fhir:CodeSystem.concept.definition [ fhir:value "Nephrectomy" ]
], [
fhir:index 24;
fhir:CodeSystem.concept.code [ fhir:value "12.4" ];
fhir:CodeSystem.concept.display [ fhir:value "Ifosfamide" ];
fhir:CodeSystem.concept.definition [ fhir:value "Ifosfamide" ]
], [
fhir:index 25;
fhir:CodeSystem.concept.code [ fhir:value "12.5" ];
fhir:CodeSystem.concept.display [ fhir:value "Platinium based chemotherapy" ];
fhir:CodeSystem.concept.definition [ fhir:value "Platinium based chemotherapy" ]
], [
fhir:index 26;
fhir:CodeSystem.concept.code [ fhir:value "12.6" ];
fhir:CodeSystem.concept.display [ fhir:value "Nitrosureas" ];
fhir:CodeSystem.concept.definition [ fhir:value "Nitrosureas" ]
], [
fhir:index 27;
fhir:CodeSystem.concept.code [ fhir:value "12.7" ];
fhir:CodeSystem.concept.display [ fhir:value "Immunosuppressives treatment and prolonged steroids as anticancer treatment (at least 4 weeks, continuously)" ];
fhir:CodeSystem.concept.definition [ fhir:value "Immunosuppressives treatment and prolonged steroids as anticancer treatment (at least 4 weeks, continuously)" ]
], [
fhir:index 28;
fhir:CodeSystem.concept.code [ fhir:value "13.1" ];
fhir:CodeSystem.concept.display [ fhir:value "Cranial and/or spinal RT" ];
fhir:CodeSystem.concept.definition [ fhir:value "Cranial and/or spinal RT" ]
], [
fhir:index 29;
fhir:CodeSystem.concept.code [ fhir:value "13.3" ];
fhir:CodeSystem.concept.display [ fhir:value "Methotrexate" ];
fhir:CodeSystem.concept.definition [ fhir:value "Methotrexate" ]
], [
fhir:index 30;
fhir:CodeSystem.concept.code [ fhir:value "13.4" ];
fhir:CodeSystem.concept.display [ fhir:value "Gonadal failure" ];
fhir:CodeSystem.concept.definition [ fhir:value "Gonadal failure" ]
], [
fhir:index 31;
fhir:CodeSystem.concept.code [ fhir:value "13.5" ];
fhir:CodeSystem.concept.display [ fhir:value "Growth hormone deficiency" ];
fhir:CodeSystem.concept.definition [ fhir:value "Growth hormone deficiency" ]
], [
fhir:index 32;
fhir:CodeSystem.concept.code [ fhir:value "13.6" ];
fhir:CodeSystem.concept.display [ fhir:value "Prolonged (at least 4 weeks, continuously) corticosteroids as anti-cancer treatment" ];
fhir:CodeSystem.concept.definition [ fhir:value "Prolonged (at least 4 weeks, continuously) corticosteroids as anti-cancer treatment" ]
], [
fhir:index 33;
fhir:CodeSystem.concept.code [ fhir:value "14.3" ];
fhir:CodeSystem.concept.display [ fhir:value "High dose RT" ];
fhir:CodeSystem.concept.definition [ fhir:value "High dose RT" ]
], [
fhir:index 34;
fhir:CodeSystem.concept.code [ fhir:value "15.1" ];
fhir:CodeSystem.concept.display [ fhir:value "Radiotherapy to a vol exposing the HP region >= 30 Gy" ];
fhir:CodeSystem.concept.definition [ fhir:value "Radiotherapy to a vol exposing the HP region >= 30 Gy" ]
], [
fhir:index 35;
fhir:CodeSystem.concept.code [ fhir:value "15.2" ];
fhir:CodeSystem.concept.display [ fhir:value "Surgery near or within the HP region" ];
fhir:CodeSystem.concept.definition [ fhir:value "Surgery near or within the HP region" ]
], [
fhir:index 36;
fhir:CodeSystem.concept.code [ fhir:value "15.3" ];
fhir:CodeSystem.concept.display [ fhir:value "CNS tumours near or within the HP region" ];
fhir:CodeSystem.concept.definition [ fhir:value "CNS tumours near or within the HP region" ]
], [
fhir:index 37;
fhir:CodeSystem.concept.code [ fhir:value "16.1" ];
fhir:CodeSystem.concept.display [ fhir:value "Radiotherapy to a vol exposing the HP region< 30 Gy" ];
fhir:CodeSystem.concept.definition [ fhir:value "Radiotherapy to a vol exposing the HP region< 30 Gy" ]
], [
fhir:index 38;
fhir:CodeSystem.concept.code [ fhir:value "16.2" ];
fhir:CodeSystem.concept.display [ fhir:value "Hydrocephalus or cerebrospinal fluid shunt (Risk factor for GHD)" ];
fhir:CodeSystem.concept.definition [ fhir:value "Hydrocephalus or cerebrospinal fluid shunt (Risk factor for GHD)" ]
], [
fhir:index 39;
fhir:CodeSystem.concept.code [ fhir:value "17.1" ];
fhir:CodeSystem.concept.display [ fhir:value "Radiotherapy to a vol exposing the HP region" ];
fhir:CodeSystem.concept.definition [ fhir:value "Radiotherapy to a vol exposing the HP region" ]
], [
fhir:index 40;
fhir:CodeSystem.concept.code [ fhir:value "17.3" ];
fhir:CodeSystem.concept.display [ fhir:value "Surgery near or within the HP region" ];
fhir:CodeSystem.concept.definition [ fhir:value "Surgery near or within the HP region" ]
], [
fhir:index 41;
fhir:CodeSystem.concept.code [ fhir:value "18.1" ];
fhir:CodeSystem.concept.display [ fhir:value "Radiotherapy to a vol exposing the HP region" ];
fhir:CodeSystem.concept.definition [ fhir:value "Radiotherapy to a vol exposing the HP region" ]
], [
fhir:index 42;
fhir:CodeSystem.concept.code [ fhir:value "18.3" ];
fhir:CodeSystem.concept.display [ fhir:value "Surgery near or within the HP region" ];
fhir:CodeSystem.concept.definition [ fhir:value "Surgery near or within the HP region" ]
], [
fhir:index 43;
fhir:CodeSystem.concept.code [ fhir:value "19.1" ];
fhir:CodeSystem.concept.display [ fhir:value "RT to a vol exposing the thyroid gland" ];
fhir:CodeSystem.concept.definition [ fhir:value "RT to a vol exposing the thyroid gland" ]
], [
fhir:index 44;
fhir:CodeSystem.concept.code [ fhir:value "19.3" ];
fhir:CodeSystem.concept.display [ fhir:value "Radioiodine therapy (I-131 ablation therapy)" ];
fhir:CodeSystem.concept.definition [ fhir:value "Radioiodine therapy (I-131 ablation therapy)" ]
], [
fhir:index 45;
fhir:CodeSystem.concept.code [ fhir:value "19.5" ];
fhir:CodeSystem.concept.display [ fhir:value "Allogenic HSCT" ];
fhir:CodeSystem.concept.definition [ fhir:value "Allogenic HSCT" ]
], [
fhir:index 46;
fhir:CodeSystem.concept.code [ fhir:value "19.6" ];
fhir:CodeSystem.concept.display [ fhir:value "Total thyroidectomy" ];
fhir:CodeSystem.concept.definition [ fhir:value "Total thyroidectomy" ]
], [
fhir:index 47;
fhir:CodeSystem.concept.code [ fhir:value "20.1" ];
fhir:CodeSystem.concept.display [ fhir:value "RT to a vol exposing the head, brain or neck" ];
fhir:CodeSystem.concept.definition [ fhir:value "RT to a vol exposing the head, brain or neck" ]
], [
fhir:index 48;
fhir:CodeSystem.concept.code [ fhir:value "21.1" ];
fhir:CodeSystem.concept.display [ fhir:value "History of a central nervous system tumor" ];
fhir:CodeSystem.concept.definition [ fhir:value "History of a central nervous system tumor" ]
], [
fhir:index 49;
fhir:CodeSystem.concept.code [ fhir:value "21.2" ];
fhir:CodeSystem.concept.display [ fhir:value "RT to a vol exposing the brain ANY DOSE" ];
fhir:CodeSystem.concept.definition [ fhir:value "RT to a vol exposing the brain ANY DOSE" ]
], [
fhir:index 50;
fhir:CodeSystem.concept.code [ fhir:value "21.4" ];
fhir:CodeSystem.concept.display [ fhir:value "Brain surgery" ];
fhir:CodeSystem.concept.definition [ fhir:value "Brain surgery" ]
], [
fhir:index 51;
fhir:CodeSystem.concept.code [ fhir:value "21.5" ];
fhir:CodeSystem.concept.display [ fhir:value "High dose cytarabine IV (intravenous)" ];
fhir:CodeSystem.concept.definition [ fhir:value "High dose cytarabine IV (intravenous)" ]
], [
fhir:index 52;
fhir:CodeSystem.concept.code [ fhir:value "21.6" ];
fhir:CodeSystem.concept.display [ fhir:value "High dose MTX IV" ];
fhir:CodeSystem.concept.definition [ fhir:value "High dose MTX IV" ]
], [
fhir:index 53;
fhir:CodeSystem.concept.code [ fhir:value "21.7" ];
fhir:CodeSystem.concept.display [ fhir:value "Any Chemotherapy IT (intrathecal)" ];
fhir:CodeSystem.concept.definition [ fhir:value "Any Chemotherapy IT (intrathecal)" ]
], [
fhir:index 54;
fhir:CodeSystem.concept.code [ fhir:value "22.1" ];
fhir:CodeSystem.concept.display [ fhir:value "Vinca-Alkaloids" ];
fhir:CodeSystem.concept.definition [ fhir:value "Vinca-Alkaloids" ]
], [
fhir:index 55;
fhir:CodeSystem.concept.code [ fhir:value "22.2" ];
fhir:CodeSystem.concept.display [ fhir:value "Cisplatin or carboplatin" ];
fhir:CodeSystem.concept.definition [ fhir:value "Cisplatin or carboplatin" ]
], [
fhir:index 56;
fhir:CodeSystem.concept.code [ fhir:value "23.1" ];
fhir:CodeSystem.concept.display [ fhir:value "RT to a vol exposing the lens" ];
fhir:CodeSystem.concept.definition [ fhir:value "RT to a vol exposing the lens" ]
], [
fhir:index 57;
fhir:CodeSystem.concept.code [ fhir:value "24.1" ];
fhir:CodeSystem.concept.display [ fhir:value "RT to a vol exposing the eye and orbit" ];
fhir:CodeSystem.concept.definition [ fhir:value "RT to a vol exposing the eye and orbit" ]
], [
fhir:index 58;
fhir:CodeSystem.concept.code [ fhir:value "24.3" ];
fhir:CodeSystem.concept.display [ fhir:value "Radioiodine therapy (I-131 ablation therapy)" ];
fhir:CodeSystem.concept.definition [ fhir:value "Radioiodine therapy (I-131 ablation therapy)" ]
], [
fhir:index 59;
fhir:CodeSystem.concept.code [ fhir:value "25.1" ];
fhir:CodeSystem.concept.display [ fhir:value "RT to a vol exposing the craniofacial area, especially after high doses and at a young age" ];
fhir:CodeSystem.concept.definition [ fhir:value "RT to a vol exposing the craniofacial area, especially after high doses and at a young age" ]
], [
fhir:index 60;
fhir:CodeSystem.concept.code [ fhir:value "25.3" ];
fhir:CodeSystem.concept.display [ fhir:value "Surgery to the face, especially at a young age" ];
fhir:CodeSystem.concept.definition [ fhir:value "Surgery to the face, especially at a young age" ]
], [
fhir:index 61;
fhir:CodeSystem.concept.code [ fhir:value "26.1" ];
fhir:CodeSystem.concept.display [ fhir:value "Surgery of the spine" ];
fhir:CodeSystem.concept.definition [ fhir:value "Surgery of the spine" ]
], [
fhir:index 62;
fhir:CodeSystem.concept.code [ fhir:value "26.2" ];
fhir:CodeSystem.concept.display [ fhir:value "Surgery of the chest (Does not include CVC pose)" ];
fhir:CodeSystem.concept.definition [ fhir:value "Surgery of the chest (Does not include CVC pose)" ]
], [
fhir:index 63;
fhir:CodeSystem.concept.code [ fhir:value "26.3" ];
fhir:CodeSystem.concept.display [ fhir:value "RT to a vol exposing the spine" ];
fhir:CodeSystem.concept.definition [ fhir:value "RT to a vol exposing the spine" ]
], [
fhir:index 64;
fhir:CodeSystem.concept.code [ fhir:value "26.4" ];
fhir:CodeSystem.concept.display [ fhir:value "Spinal or paraspinal malignancies" ];
fhir:CodeSystem.concept.definition [ fhir:value "Spinal or paraspinal malignancies" ]
], [
fhir:index 65;
fhir:CodeSystem.concept.code [ fhir:value "27.1" ];
fhir:CodeSystem.concept.display [ fhir:value "Cyclophosphamide" ];
fhir:CodeSystem.concept.definition [ fhir:value "Cyclophosphamide" ]
], [
fhir:index 66;
fhir:CodeSystem.concept.code [ fhir:value "27.3" ];
fhir:CodeSystem.concept.display [ fhir:value "RT to a vol exposing the bladder" ];
fhir:CodeSystem.concept.definition [ fhir:value "RT to a vol exposing the bladder" ]
], [
fhir:index 67;
fhir:CodeSystem.concept.code [ fhir:value "27.5" ];
fhir:CodeSystem.concept.display [ fhir:value "Cystectomy" ];
fhir:CodeSystem.concept.definition [ fhir:value "Cystectomy" ]
], [
fhir:index 68;
fhir:CodeSystem.concept.code [ fhir:value "27.6" ];
fhir:CodeSystem.concept.display [ fhir:value "Hysterectomy" ];
fhir:CodeSystem.concept.definition [ fhir:value "Hysterectomy" ]
], [
fhir:index 69;
fhir:CodeSystem.concept.code [ fhir:value "27.7" ];
fhir:CodeSystem.concept.display [ fhir:value "Pelvic surgery" ];
fhir:CodeSystem.concept.definition [ fhir:value "Pelvic surgery" ]
], [
fhir:index 70;
fhir:CodeSystem.concept.code [ fhir:value "27.8" ];
fhir:CodeSystem.concept.display [ fhir:value "Spinal cord surgery" ];
fhir:CodeSystem.concept.definition [ fhir:value "Spinal cord surgery" ]
], [
fhir:index 71;
fhir:CodeSystem.concept.code [ fhir:value "28.1" ];
fhir:CodeSystem.concept.display [ fhir:value "RT to a vol exposing the uterus only female" ];
fhir:CodeSystem.concept.definition [ fhir:value "RT to a vol exposing the uterus only female" ]
], [
fhir:index 72;
fhir:CodeSystem.concept.code [ fhir:value "29.1" ];
fhir:CodeSystem.concept.display [ fhir:value "RT to a vol exposing the oral cavity or salivary glands" ];
fhir:CodeSystem.concept.definition [ fhir:value "RT to a vol exposing the oral cavity or salivary glands" ]
], [
fhir:index 73;
fhir:CodeSystem.concept.code [ fhir:value "29.4" ];
fhir:CodeSystem.concept.display [ fhir:value "Chemotherapy" ];
fhir:CodeSystem.concept.definition [ fhir:value "Chemotherapy" ]
], [
fhir:index 74;
fhir:CodeSystem.concept.code [ fhir:value "30.1" ];
fhir:CodeSystem.concept.display [ fhir:value "RT to a vol exposing the gastro-intestinal tract" ];
fhir:CodeSystem.concept.definition [ fhir:value "RT to a vol exposing the gastro-intestinal tract" ]
], [
fhir:index 75;
fhir:CodeSystem.concept.code [ fhir:value "30.3" ];
fhir:CodeSystem.concept.display [ fhir:value "Oesophageal surgery" ];
fhir:CodeSystem.concept.definition [ fhir:value "Oesophageal surgery" ]
], [
fhir:index 76;
fhir:CodeSystem.concept.code [ fhir:value "30.4" ];
fhir:CodeSystem.concept.display [ fhir:value "Abdominal surgery" ];
fhir:CodeSystem.concept.definition [ fhir:value "Abdominal surgery" ]
], [
fhir:index 77;
fhir:CodeSystem.concept.code [ fhir:value "30.5" ];
fhir:CodeSystem.concept.display [ fhir:value "With a history of chronic GVHD" ];
fhir:CodeSystem.concept.definition [ fhir:value "With a history of chronic GVHD" ]
], [
fhir:index 78;
fhir:CodeSystem.concept.code [ fhir:value "31.1" ];
fhir:CodeSystem.concept.display [ fhir:value "Anthracyclines (doxorubicin isotoxic equivalents) <100 mg/m2" ];
fhir:CodeSystem.concept.definition [ fhir:value "Anthracyclines (doxorubicin isotoxic equivalents) <100 mg/m2" ]
], [
fhir:index 79;
fhir:CodeSystem.concept.code [ fhir:value "32.1" ];
fhir:CodeSystem.concept.display [ fhir:value "RT to a vol exposing the lungs" ];
fhir:CodeSystem.concept.definition [ fhir:value "RT to a vol exposing the lungs" ]
], [
fhir:index 80;
fhir:CodeSystem.concept.code [ fhir:value "32.3" ];
fhir:CodeSystem.concept.display [ fhir:value "Bleomycin" ];
fhir:CodeSystem.concept.definition [ fhir:value "Bleomycin" ]
], [
fhir:index 81;
fhir:CodeSystem.concept.code [ fhir:value "32.4" ];
fhir:CodeSystem.concept.display [ fhir:value "Busulfan" ];
fhir:CodeSystem.concept.definition [ fhir:value "Busulfan" ]
], [
fhir:index 82;
fhir:CodeSystem.concept.code [ fhir:value "32.5" ];
fhir:CodeSystem.concept.display [ fhir:value "BCNU Carmustine" ];
fhir:CodeSystem.concept.definition [ fhir:value "BCNU Carmustine" ]
], [
fhir:index 83;
fhir:CodeSystem.concept.code [ fhir:value "32.6" ];
fhir:CodeSystem.concept.display [ fhir:value "CCNU Lomustine" ];
fhir:CodeSystem.concept.definition [ fhir:value "CCNU Lomustine" ]
], [
fhir:index 84;
fhir:CodeSystem.concept.code [ fhir:value "32.7" ];
fhir:CodeSystem.concept.display [ fhir:value "Thoracic surgery" ];
fhir:CodeSystem.concept.definition [ fhir:value "Thoracic surgery" ]
], [
fhir:index 85;
fhir:CodeSystem.concept.code [ fhir:value "33.1" ];
fhir:CodeSystem.concept.display [ fhir:value "Cisplatin Any dose" ];
fhir:CodeSystem.concept.definition [ fhir:value "Cisplatin Any dose" ]
], [
fhir:index 86;
fhir:CodeSystem.concept.code [ fhir:value "33.3" ];
fhir:CodeSystem.concept.display [ fhir:value "Carboplatin Any dose" ];
fhir:CodeSystem.concept.definition [ fhir:value "Carboplatin Any dose" ]
], [
fhir:index 87;
fhir:CodeSystem.concept.code [ fhir:value "34.1" ];
fhir:CodeSystem.concept.display [ fhir:value "RT to a volume exposing the liver" ];
fhir:CodeSystem.concept.definition [ fhir:value "RT to a volume exposing the liver" ]
], [
fhir:index 88;
fhir:CodeSystem.concept.code [ fhir:value "34.3" ];
fhir:CodeSystem.concept.display [ fhir:value "HSCT (irrespective of GVHD)" ];
fhir:CodeSystem.concept.definition [ fhir:value "HSCT (irrespective of GVHD)" ]
], [
fhir:index 89;
fhir:CodeSystem.concept.code [ fhir:value "34.5" ];
fhir:CodeSystem.concept.display [ fhir:value "Mercaptopurine Thioguanine" ];
fhir:CodeSystem.concept.definition [ fhir:value "Mercaptopurine Thioguanine" ]
], [
fhir:index 90;
fhir:CodeSystem.concept.code [ fhir:value "34.6" ];
fhir:CodeSystem.concept.display [ fhir:value "Dactinomycin" ];
fhir:CodeSystem.concept.definition [ fhir:value "Dactinomycin" ]
], [
fhir:index 91;
fhir:CodeSystem.concept.code [ fhir:value "34.8" ];
fhir:CodeSystem.concept.display [ fhir:value "Chronic viral hepatitis" ];
fhir:CodeSystem.concept.definition [ fhir:value "Chronic viral hepatitis" ]
], [
fhir:index 92;
fhir:CodeSystem.concept.code [ fhir:value "34.9" ];
fhir:CodeSystem.concept.display [ fhir:value "Sinusoidal obstruction syndrome" ];
fhir:CodeSystem.concept.definition [ fhir:value "Sinusoidal obstruction syndrome" ]
], [
fhir:index 93;
fhir:CodeSystem.concept.code [ fhir:value "34.10" ];
fhir:CodeSystem.concept.display [ fhir:value "Chronic GVHD" ];
fhir:CodeSystem.concept.definition [ fhir:value "Chronic GVHD" ]
], [
fhir:index 94;
fhir:CodeSystem.concept.code [ fhir:value "34.11" ];
fhir:CodeSystem.concept.display [ fhir:value "Liver surgery" ];
fhir:CodeSystem.concept.definition [ fhir:value "Liver surgery" ]
], [
fhir:index 95;
fhir:CodeSystem.concept.code [ fhir:value "35.2" ];
fhir:CodeSystem.concept.display [ fhir:value "Multiple red blood cell transfusions" ];
fhir:CodeSystem.concept.definition [ fhir:value "Multiple red blood cell transfusions" ]
], [
fhir:index 96;
fhir:CodeSystem.concept.code [ fhir:value "36.1" ];
fhir:CodeSystem.concept.display [ fhir:value "Splenectomy" ];
fhir:CodeSystem.concept.definition [ fhir:value "Splenectomy" ]
], [
fhir:index 97;
fhir:CodeSystem.concept.code [ fhir:value "36.2" ];
fhir:CodeSystem.concept.display [ fhir:value "RT >= 10 Gy to a vol exposing the spleen" ];
fhir:CodeSystem.concept.definition [ fhir:value "RT >= 10 Gy to a vol exposing the spleen" ]
], [
fhir:index 98;
fhir:CodeSystem.concept.code [ fhir:value "36.4" ];
fhir:CodeSystem.concept.display [ fhir:value "Autologus HSCT conditioned with TBI" ];
fhir:CodeSystem.concept.definition [ fhir:value "Autologus HSCT conditioned with TBI" ]
], [
fhir:index 99;
fhir:CodeSystem.concept.code [ fhir:value "37.1" ];
fhir:CodeSystem.concept.display [ fhir:value "Hereditary cancer sd" ];
fhir:CodeSystem.concept.definition [ fhir:value "Hereditary cancer sd" ]
], [
fhir:index 100;
fhir:CodeSystem.concept.code [ fhir:value "38.1" ];
fhir:CodeSystem.concept.display [ fhir:value "Any RT including TBI" ];
fhir:CodeSystem.concept.definition [ fhir:value "Any RT including TBI" ]
], [
fhir:index 101;
fhir:CodeSystem.concept.code [ fhir:value "39.1" ];
fhir:CodeSystem.concept.display [ fhir:value "RT to a vol exposing the colon and rectum" ];
fhir:CodeSystem.concept.definition [ fhir:value "RT to a vol exposing the colon and rectum" ]
], [
fhir:index 102;
fhir:CodeSystem.concept.code [ fhir:value "40.1" ];
fhir:CodeSystem.concept.display [ fhir:value "RT to a vol exposing the oral cavity" ];
fhir:CodeSystem.concept.definition [ fhir:value "RT to a vol exposing the oral cavity" ]
], [
fhir:index 103;
fhir:CodeSystem.concept.code [ fhir:value "41.2" ];
fhir:CodeSystem.concept.display [ fhir:value "Anthracyclines and/or Mitoxantrone" ];
fhir:CodeSystem.concept.definition [ fhir:value "Anthracyclines and/or Mitoxantrone" ]
], [
fhir:index 104;
fhir:CodeSystem.concept.code [ fhir:value "41.3" ];
fhir:CodeSystem.concept.display [ fhir:value "Epipodophyllotoxins or autologous" ];
fhir:CodeSystem.concept.definition [ fhir:value "Epipodophyllotoxins or autologous" ]
], [
fhir:index 105;
fhir:CodeSystem.concept.code [ fhir:value "41.4" ];
fhir:CodeSystem.concept.display [ fhir:value "Autologous haematopoietic stem cell transplant" ];
fhir:CodeSystem.concept.definition [ fhir:value "Autologous haematopoietic stem cell transplant" ]
], [
fhir:index 106;
fhir:CodeSystem.concept.code [ fhir:value "42.1" ];
fhir:CodeSystem.concept.display [ fhir:value "Ciclofosfamide, Ifosfamide (particularly if they have a history of severe hemorrhagic cystitis)" ];
fhir:CodeSystem.concept.definition [ fhir:value "Ciclofosfamide, Ifosfamide (particularly if they have a history of severe hemorrhagic cystitis)" ]
], [
fhir:index 107;
fhir:CodeSystem.concept.code [ fhir:value "42.2" ];
fhir:CodeSystem.concept.display [ fhir:value "RT to a vol exposing the bladder" ];
fhir:CodeSystem.concept.definition [ fhir:value "RT to a vol exposing the bladder" ]
], [
fhir:index 108;
fhir:CodeSystem.concept.code [ fhir:value "44.1" ];
fhir:CodeSystem.concept.display [ fhir:value "RT to a vol exposing the lungs" ];
fhir:CodeSystem.concept.definition [ fhir:value "RT to a vol exposing the lungs" ]
], [
fhir:index 109;
fhir:CodeSystem.concept.code [ fhir:value "45.1" ];
fhir:CodeSystem.concept.display [ fhir:value "RT to a vol exposing the head or brain" ];
fhir:CodeSystem.concept.definition [ fhir:value "RT to a vol exposing the head or brain" ]
], [
fhir:index 110;
fhir:CodeSystem.concept.code [ fhir:value "46.2" ];
fhir:CodeSystem.concept.display [ fhir:value "Anthracyclines (doxorubicin isotoxic equivalents) between 100 and 250 mg/m2" ];
fhir:CodeSystem.concept.definition [ fhir:value "Anthracyclines (doxorubicin isotoxic equivalents) between 100 and 250 mg/m2" ]
], [
fhir:index 111;
fhir:CodeSystem.concept.code [ fhir:value "47.1" ];
fhir:CodeSystem.concept.display [ fhir:value "RT to a vol exposing the kidney or urinary tract" ];
fhir:CodeSystem.concept.definition [ fhir:value "RT to a vol exposing the kidney or urinary tract" ]
]. #
# - ontology header ------------------------------------------------------------
a owl:Ontology;
owl:imports fhir:fhir.ttl.
IG © 2021+ PanCareSurPass Project. Package hl7.eu.fhir.pcsp#0.1.0 based on FHIR 4.0.1. Generated 2023-01-26
Links: Table of Contents |
QA Report
The PanCareSurPass Research and Innovation Action has received funding from the European Union's Horizon 2020
research and innovation programme under grant agreement No. 899999.
